Pharma News

Obesity and eating fatty food are significant risk factors for many types of cancer. A new study has revealed that a high-fat diet makes the cells of the intestinal lining in the gut more likely to become cancerous.

Common asthma symptoms are associated with increased levels of stress and anxiety in teens, a study has found.A study by Henry Ford Hospital in Detroit city of Michigan state in the US has found in a small study of 38 asthma patients aged 14-17, that their average scores for stress and anxiety levels were higher than those seen in the general population.

Consuming foods and beverages with a high glycemic index, such as white bread or bagels, corn flakes and puffed rice, is linked with an increased risk of developing lung cancer, says a study.

Baxalta Incorporated announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval of ADYNOVI, an extended circulating half-life recombinant Factor VIII (rFVIII) treatment, for pediatric, adolescent and adult patients with hemophilia A and for use during surgery. Currently licensed in the U.S. as ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] and under regulatory review in Japan, Canada and Switzerland, ADYNOVI is the only rFVIII treatment for hemophilia A developed based on the demonstrated efficacy of ADVATE [Antihemophilic Factor (Recombinant)].

BioMarin Pharmaceutical Inc. announced positive 48-week results from its Phase 1/2 pivotal study for cerliponase alfa, a recombinant human tripeptidyl peptidase 1 (rhTPP1) to treat children with CLN2 disease, a form of Batten disease.  CLN2 disease is a rapidly progressing, fatal neurodegenerative disease with no approved treatments, where the majority of affected children lose their ability to walk and talk by approximately six years of age.

[adsense:336x280:8701650588]

Sangamo BioSciences, Inc. announced the presentation of new preclinical data in disease models from its In Vivo Protein Replacement Platform™ (IVPRP) programs for MPS I (Hurler syndrome) and MPS II (Hunter syndrome). The data demonstrate that the Company's IVPRP approach enabled stable production of therapeutic levels of replacement enzyme from the liver into the circulation and secondary tissues, including the brain, resulting in significant reduction in biomarkers of the disease and, importantly, statistically significant improvements in cognitive function in treated animals.

Sanofi and its specialty care global business unit Sanofi Genzyme presented data from NEO1, its Phase 1/2 clinical study evaluating the investigational novel enzyme replacement therapy neoGAA in 24 patients with late-onset Pompe disease.

Decreased opioid use prior to joint replacement surgery has been linked with improved patient satisfaction and outcomes, fewer complications and a reduced need for post-surgical opioids, according to two new studies.

A Zika virus-laden mosquito bite may infect and kill a type of brain cell, vital for the development of the brain, says a new study conducted in lab grown human cells.

Regular usage of aspirin is likely to reduce the overall risk of cancer, a reduction that primarily reflects a lower risk of colorectal cancer and other tumours of the gastrointestinal tracts, finds a new study.